The Inflation Reduction Act, signed into law in August 2022, did something that Washington had debated and failed to accomplish for decades: it gave Medicare the power to negotiate drug prices directly with pharmaceutical manufacturers. The first ten negotiated prices took effect on January 1, 2026, delivering discounts ranging from 38% to 79% off 2023 list prices and saving the Medicare program an estimated $6 billion per year. For the roughly 9 million enrollees who rely on these medications, out-of-pocket costs dropped by an average of 51%, according to an AARP analysis of 56 stand-alone Part D plans. That is not a rounding error.
That is the difference between affording your prescriptions and splitting pills to make them last. But price negotiation was only one piece of what the law did. It also capped insulin copays at $35 a month for Medicare beneficiaries, eliminated cost-sharing on recommended vaccines, imposed inflation penalties on drugmakers who hike prices faster than the cost of living, and — perhaps most consequentially for people managing expensive chronic conditions — placed a hard annual cap on out-of-pocket Part D spending that previously had no limit at all. For families navigating dementia care, where medication regimens are often complex and costly, these changes reshaped the financial landscape in ways worth understanding in detail. This article walks through each major provision, what it actually changed, where the limitations are, and what comes next.
Table of Contents
- How Did Medicare Drug Price Negotiation Actually Work?
- What Does the $35 Insulin Cap Mean in Practice — and Who Does It Miss?
- The $2,000 Out-of-Pocket Cap and Why It Matters for Dementia Families
- Free Vaccines and Inflation Penalties — the Provisions That Got Less Attention
- What the Law Does Not Cover and Where Gaps Remain
- The Second Wave — 15 More Drugs Coming in 2027
- What Comes Next for Drug Pricing and Medicare
- Conclusion
- Frequently Asked Questions
How Did Medicare Drug Price Negotiation Actually Work?
For decades, Medicare was explicitly prohibited from negotiating prescription drug prices. Private insurers, the Veterans Administration, and Medicaid all had some form of negotiating leverage, but Medicare — the single largest purchaser of prescription drugs in the country — was required by law to accept whatever price manufacturers set. The Inflation Reduction Act changed that by directing the Centers for Medicare and Medicaid Services to identify the highest-cost drugs without generic competition and negotiate maximum fair prices directly with their makers. The first round targeted ten Part D drugs that collectively accounted for enormous Medicare spending. These included treatments for diabetes, heart failure, blood clots, cancer, autoimmune disease, and chronic kidney disease — all brand-name medications with no generic alternatives available. The negotiated discounts varied widely.
Januvia, a diabetes drug, saw the steepest reduction at 79% off its 2023 list price. Imbruvica, used for blood cancers, received the smallest cut at 38%. Stelara, used for autoimmune conditions, may deliver the largest dollar savings for individual enrollees — average monthly costs could drop by $5,046, a 68% reduction, according to CMS projections. It is worth noting what the first round did not cover. Only ten drugs were included, and they were selected based on Medicare spending data, not on how many patients they affect or how burdensome costs are for individuals. Many expensive medications — including several used in neurological care — were not part of this initial group. The program is designed to scale, but for 2026, the impact was concentrated on a specific set of high-cost treatments.
What Does the $35 Insulin Cap Mean in Practice — and Who Does It Miss?
One of the most widely publicized provisions was the $35 monthly cap on insulin copays for medicare Part D enrollees, which took effect January 1, 2023. A corresponding cap for Medicare Part B insulin (typically administered in clinical settings) followed on July 1, 2023. Roughly 1.5 million Medicare beneficiaries who use insulin experienced direct savings. HHS estimated that had the cap been in place during 2020, it would have saved beneficiaries $734 million in Part D costs alone, plus another $27 million through Part B. The cap also appears to have improved medication adherence.
Research from the USC Schaeffer Center found that insulin prescription fills increased after the cap took effect — rising from 519,588 to 523,564 per month among Part D enrollees. That may sound modest in percentage terms, but it represents thousands of people who were likely rationing or skipping doses due to cost and who resumed consistent use once the financial barrier dropped. However, if you are not on Medicare, this cap does not apply to you. The Inflation Reduction Act’s insulin provision covers only Medicare beneficiaries. People with private insurance or no insurance at all were not included in the federal mandate, though some manufacturers and states have since adopted their own caps in response to public pressure. For caregivers managing a loved one’s diabetes alongside dementia — a common comorbidity — the savings are real but only if the person is enrolled in Medicare Part D or Part B.
The $2,000 Out-of-Pocket Cap and Why It Matters for Dementia Families
Before the Inflation Reduction Act, Medicare Part D had no hard cap on annual out-of-pocket drug spending. Beneficiaries who needed expensive specialty medications could face costs that climbed into the tens of thousands of dollars per year. The so-called “catastrophic” phase of Part D coverage still required patients to pay 5% of drug costs indefinitely — and 5% of a $150,000 annual drug regimen is $7,500 out of pocket, every year, with no ceiling. Starting in 2025, the law imposed a hard annual cap of $2,000 on out-of-pocket Part D spending. Once a beneficiary hits that threshold, their plan covers 100% of remaining drug costs for the rest of the calendar year.
The cap adjusts slightly for inflation — it rises to $2,100 in 2026. For someone managing dementia care, where the affected person may be taking cholinesterase inhibitors, antipsychotics, medications for co-occurring conditions like diabetes or cardiovascular disease, and over-the-counter supplements, this cap provides a predictable maximum that makes financial planning possible. Consider a specific scenario: a Medicare beneficiary taking a brand-name Alzheimer’s medication alongside drugs for high blood pressure and Type 2 diabetes. Before the cap, their annual out-of-pocket drug costs might have exceeded $4,000 or $5,000 depending on their plan’s formulary. Under the new rules, once they reach $2,000 in a given year, every subsequent prescription for the rest of that year costs them nothing. That predictability alone is a significant shift for families already stretched thin by the costs of caregiving.
Free Vaccines and Inflation Penalties — the Provisions That Got Less Attention
Two other provisions of the Inflation Reduction Act received less media coverage but carry meaningful implications. First, starting in 2023, all recommended vaccines under Medicare Part D became free — no copays, no cost-sharing. This includes shingles vaccines (which previously could cost seniors $200 or more out of pocket), Tdap boosters, and other immunizations recommended by the Advisory Committee on Immunization Practices. For older adults, particularly those in congregate care settings or with compromised immune function, removing the cost barrier to vaccination is a straightforward public health win. Second, the law introduced inflation rebate penalties. If a drug manufacturer raises the price of a Medicare-covered drug faster than the rate of inflation, the company must pay a rebate back to Medicare.
This is a guardrail, not a price control — it does not prevent price increases, but it makes excessive increases financially painful for manufacturers. The tradeoff is that this mechanism only applies to drugs already on the market. It does nothing to constrain launch prices for new medications, which is where some of the most aggressive pricing in the pharmaceutical industry occurs. A company can still bring a new drug to market at $100,000 a year; the inflation penalty only kicks in if they then try to raise that price faster than the Consumer Price Index in subsequent years. For dementia families weighing the cost of current versus emerging therapies, this distinction matters. Newer Alzheimer’s treatments — including anti-amyloid antibodies — entered the market at high price points, and the inflation rebate mechanism does not address those initial costs. It protects against future gouging on existing drugs, but the sticker shock on new ones remains an unresolved problem.
What the Law Does Not Cover and Where Gaps Remain
The Inflation Reduction Act was the most significant pharmaceutical pricing legislation in a generation, but it has clear boundaries. The drug negotiation program starts small and ramps up gradually: 10 drugs in 2026, 15 in 2027 and 2028, and 20 per year from 2029 onward. At that pace, it will take years before the program touches more than a fraction of the thousands of brand-name drugs on the market. Manufacturers have also filed lawsuits challenging the program’s constitutionality, and while those challenges have so far been unsuccessful, they introduce legal uncertainty about the program’s long-term trajectory. There is also a warning for anyone assuming these savings automatically appear in their bills. The negotiated prices apply specifically to Medicare.
If you or your loved one has coverage through a private insurer, a Medicare Advantage plan with unusual formulary restrictions, or no insurance at all, the benefits may not translate directly. Medicare Advantage plans must cover the negotiated drugs at the negotiated prices, but cost-sharing structures vary by plan. It is worth checking with your specific plan to understand how the savings flow through to your actual copays and coinsurance. Finally, the law does not address the broader dysfunction in how drugs are priced in the United States. It negotiates within the existing system rather than overhauling it. Pharmacy benefit managers, rebate structures, formulary placement incentives — these intermediary layers that add cost and complexity remain largely untouched. For families trying to understand why a generic medication costs $15 at one pharmacy and $90 at another, the Inflation Reduction Act offers no answers.
The Second Wave — 15 More Drugs Coming in 2027
In January 2025, HHS announced the selection of 15 additional Part D drugs for the second round of price negotiations, with negotiated prices set to take effect January 1, 2027. This round notably includes blockbuster GLP-1 medications used for diabetes and weight loss — drugs that have generated enormous spending growth in Medicare and across the healthcare system. The inclusion of these medications signals that the negotiation program is targeting drugs based on spending impact, which means high-volume, high-cost medications are most likely to be selected in future rounds.
For families managing dementia alongside metabolic conditions, this second wave could be consequential. Type 2 diabetes is a known risk factor for cognitive decline, and many people with dementia also manage diabetes. If GLP-1 medications emerge from negotiation with meaningful discounts, it could reduce costs for a population that disproportionately needs them. But until the negotiated prices are finalized — expected later in 2026 — the exact savings remain unknown.
What Comes Next for Drug Pricing and Medicare
The negotiation program’s trajectory is set to expand significantly in coming years. By 2029, Medicare will negotiate prices for 20 drugs annually, steadily broadening the pool of medications subject to government pricing leverage. Whether that pace is fast enough depends on your perspective — patient advocacy groups argue it should move faster, while pharmaceutical companies contend it already threatens innovation funding.
The political durability of the program will likely depend on whether the early rounds produce savings that voters can feel directly at the pharmacy counter. For those caring for someone with dementia or managing their own brain health, the practical takeaway is this: the landscape of drug costs under Medicare is shifting in a more favorable direction, but slowly and unevenly. Staying informed about which drugs are negotiated, understanding your plan’s formulary, and taking advantage of provisions like the out-of-pocket cap and free vaccines are concrete steps that can reduce costs now, rather than waiting for the program to expand to every medication that matters to you.
Conclusion
The Inflation Reduction Act delivered the first real structural changes to Medicare drug pricing in nearly two decades. Its negotiation program, insulin caps, out-of-pocket spending limits, free vaccines, and inflation penalties collectively represent a meaningful shift for millions of beneficiaries — particularly those managing chronic conditions that require expensive, ongoing medication. The estimated $6 billion in annual Medicare savings and $1.5 billion in reduced out-of-pocket costs are not projections from advocates; they are figures calculated from the actual negotiated prices now in effect. The law is not a complete fix.
It does not control launch prices for new drugs, it covers only Medicare beneficiaries, and the negotiation program will take years to reach more than a small percentage of brand-name medications. For dementia families juggling multiple prescriptions across multiple conditions, the most important steps right now are confirming whether any current medications are among the negotiated drugs, understanding the $2,000 annual out-of-pocket cap, and verifying that recommended vaccines are being received at no cost. These are not abstract policy wins. They are line items on your pharmacy bill that should look different — and for many people, already do.
Frequently Asked Questions
Does the $35 insulin cap apply to people with private insurance?
No. The Inflation Reduction Act’s insulin cap applies only to Medicare beneficiaries enrolled in Part D or Part B. Some private insurers and states have adopted similar caps independently, but the federal mandate covers Medicare exclusively.
Which drugs have negotiated prices in 2026?
The first 10 drugs negotiated include treatments for diabetes, heart failure, blood clots, cancer, autoimmune conditions, and chronic kidney disease. Discounts range from 38% to 79% off 2023 list prices. A second round of 15 drugs, including GLP-1 medications, takes effect in 2027.
Is there still a donut hole in Medicare Part D?
The traditional coverage gap has been effectively replaced by the new $2,000 annual out-of-pocket cap (rising to $2,100 in 2026). Once you hit that amount, your plan covers 100% of drug costs for the remainder of the year — there is no longer a phase where you pay a disproportionate share.
Do the negotiated drug prices apply to Medicare Advantage plans?
Yes. Medicare Advantage plans that include Part D coverage must offer the negotiated drugs at the negotiated prices. However, cost-sharing structures (copays, coinsurance) vary by plan, so your actual out-of-pocket amount may differ from someone on a stand-alone Part D plan.
What happens if a drug company raises prices faster than inflation?
The manufacturer must pay a rebate back to Medicare. This inflation penalty is designed to discourage above-inflation price hikes on existing drugs, though it does not prevent companies from setting high launch prices for new medications.
Are any Alzheimer’s or dementia drugs included in the negotiated list?
The first two rounds of negotiations did not specifically include Alzheimer’s drugs. The program selects drugs based on total Medicare spending, so a dementia medication would need to rank among the highest-cost Part D drugs to be selected in future rounds. The program expands to 20 drugs per year starting in 2029.
